Candidemia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Cidara Therapeutics, Mundipharma, Pfizer

DelveInsight’s “Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Candidemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Candidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Candidemia Market Insights

Candidemia Overview

Candidemia is a serious, life-threatening bloodstream infection and possibly the fourth most common all-type bloodstream infections seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.

Some of the key facts of the Candidemia Market Report: 

• The Candidemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Rezafungin was approved by the Antimicrobial Drugs Advisory Committee of the US Food and Drug Administration (FDA) to treat candidemia and invasive candidiasis in adult patients by a vote of 14 to 1. This was announced by Cidara Therapeutics and Melinta Therapeutics. The FDA’s advisory group found that the new drug application for rezafungin had enough data to warrant a favorable risk-benefit analysis of the treatment
• The total diagnosed incident population of Candidemia in the 7MM countries was estimated to be more than 40,000 cases in 2020, with the United States, contributing approximately 23,337 cases in 2020, 55% of incident candidemia patients were males whereas 45% were females, in Japan
• Among the European countries, Spain had the highest population of candidemia with approximately 6,214 cases, followed by Germany, which had approximately 3,457 cases in 2020
• Key Candidemia Companies: Cidara Therapeutics/Mundipharma, Pfizer (acquired Amplyx Pharmaceuticals), and others
• Key Candidemia Therapies: Rezafungin, Fosmanogepix, and others
• The Candidemia epidemiology based on gender analyzed that Candidemia is slightly more prominent in males in comparison to females

Get a Free sample for the Candidemia Market Report – 

https://www.delveinsight.com/sample-request/candidemia-market

Key benefits of the Candidemia Market report:

1. Candidemia market report covers a descriptive overview and comprehensive insight of the Candidemia Epidemiology and Candidemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Candidemia market report provides insights on the current and emerging therapies.
3. Candidemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Candidemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Candidemia market.

Download the report to understand which factors are driving Candidemia epidemiology trends @ Candidemia Epidemiological Insights 

Candidemia Market  

The dynamics of the Candidemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Basilea has focused on anti-infectives, specifically antifungals and antibiotics. The company has successfully brought two anti-infective drugs to the market: the antifungal CRESEMBA (isavuconazole) and the antibiotic ZEVTERA (ceftobiprole). ISAVUCONAZOLE (BAL8557) drug’s evaluation in the Phase III trial was completed for the treatment of candidemia in 2015, after which there is no update of the drug for Candidemia treatment.”

Candidemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Candidemia Epidemiology Segmentation:

The Candidemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Candidemia
• Prevalent Cases of Candidemia by severity
• Gender-specific Prevalence of Candidemia
• Diagnosed Cases of Episodic and Chronic Candidemia

Candidemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Candidemia market or expected to get launched during the study period. The analysis covers Candidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Candidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Candidemia market share @ Candidemia market forecast

Candidemia Therapies and Key Companies

• Rezafungin: Cidara Therapeutics/Mundipharma
• Fosmanogepix: Pfizer (acquired AmplyxPharmaceuticals)

Candidemia Market Drivers

• Upcoming launch of novel, new class anti-fungal drugs
• Increasing awareness for treating Candidemia
• Personalized treatments

Scope of the Candidemia Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Candidemia Companies: Cidara Therapeutics/Mundipharma, Pfizer (acquired Amplyx Pharmaceuticals), and others
• Key Candidemia Therapies: Rezafungin, Fosmanogepix, and others
• Candidemia Therapeutic Assessment: Candidemia current marketed and Candidemia emerging therapies
• Candidemia Market Dynamics: Candidemia market drivers and Candidemia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Candidemia Unmet Needs, KOL’s views, Analyst’s views, Candidemia Market Access and Reimbursement 

Candidemia Market Barriers

• Minimizing the use of antimicrobial
• Lack of adequate diagnosis
• Lack of country-specific guidelines

Table of Contents 

1. Candidemia Market Report Introduction

2. Executive Summary for Candidemia

3. SWOT analysis of Candidemia

4. Candidemia Patient Share (%) Overview at a Glance

5. Candidemia Market Overview at a Glance

6. Candidemia Disease Background and Overview

7. Candidemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Candidemia 

9. Candidemia Current Treatment and Medical Practices

10. Candidemia Unmet Needs

11. Candidemia Emerging Therapies

12. Candidemia Market Outlook

13. Country-Wise Candidemia Market Analysis (2019–2032)

14. Candidemia Market Access and Reimbursement of Therapies

15. Candidemia Market Drivers

16. Candidemia Market Barriers

17.  Candidemia Appendix

18. Candidemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Candidemia treatment, visit @ Candidemia Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services